AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY

氨基胍在患有明显糖尿病肾病的糖尿病患者中的应用

• 批准号: 6114128
• 负责人: JANE E REUSCH
• 金额: $ 3.22万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6114128
• 关键词: aminoguanidine; chemoprevention; clinical research; diabetes mellitus therapy; diabetic nephropathy; diabetic retinopathy; drug screening /evaluation; human subject; human therapy evaluation; kidney disorder chemotherapy; medical complication

Hyperglycemia can lead to irreversible tissue damage by mediating a number of biochemical and structural protein alterations. One of these known changes involves the formation of advanced glycated endproducts or AGEs which may interact with excessive levels of blood glucose (hyperglycemia) that eventually cause the complications associated with diabetes mellitus. Pharmacologic inhibition of age-mediated protein crosslinking by aminoguanidine hydrochloride (pimagedine) may prevent and/or stabilize the development and progression of complications of diabetes, specifically retinopathy and nephropathy.

高血压可通过介导许多生化和结构蛋白质改变而导致不可逆的组织损伤。这些已知的变化之一涉及晚期糖化终产物或AGE的形成，其可与过高水平的血糖（高血糖症）相互作用，最终引起与糖尿病相关的并发症。盐酸氨基胍（匹马定）对年龄介导的蛋白质交联的药理学抑制可以预防和/或稳定糖尿病并发症（特别是视网膜病变和肾病）的发生和进展。